title: High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.
authors.forename: Wenrong
authors.initials: W
authors.lastname: Huang
authors.forename: Jian
authors.initials: J
authors.lastname: Li
authors.forename: Honghua
authors.initials: H
authors.lastname: Li
authors.forename: Wenying
authors.initials: W
authors.lastname: Kang
authors.forename: Jian
authors.initials: J
authors.lastname: Bo
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhao
authors.forename: Chunji
authors.initials: C
authors.lastname: Gao
authors.forename: Daobin
authors.initials: D
authors.lastname: Zhou
authors.forename: Li
authors.initials: L
authors.lastname: Yu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000209:etiology; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy / Q000009:adverse effects / Q000379:methods*; D053208:Kaplan-Meier Estimate; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000628:therapy*; D009325:Nausea / Q000209:etiology; D009503:Neutropenia / Q000209:etiology; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D008558:Melphalan